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Original Article
Abstract
Purpose: Radiation to brain causes early, early-delayed, and delayed side effects. There is paucity of literature regarding ear-
ly-delayed effects like somnolence syndrome. Existing studies use general symptom assessment and visual analog scales. Ep-
worth Sleepiness Scale (ESS) is a time tested tool to assess daytime sleepiness in various conditions. In this study, the ESS has
been used to determine the occurrence of somnolence in patients receiving cranial radiotherapy for primary and metastatic
brain tumors. Thus the ESS has been used in a novel setting in our study. The ESS is a simple to administer questionnaire and
may be useful in grading the severity of somnolence. To our knowledge, this is the second study to determine post radiation
somnolence using ESS. Methods: This prospective study was conducted in 23 patients with primary and metastatic brain tumor.
Patient demographics and tumor type and grade was noted. Those with Karnofsky Performance Scale (KPS) less than 70 and
with pre-existing sleep disorders were excluded. Radiotherapy regimen included palliative whole brain radiation for brain me-
tastases and conformal adjuvant radiotherapy for primary brain tumors as per standard guidelines. All subjects included were
administered ESS at baseline and weekly thereafter during and for 6 weeks after radiation. Results: All 23 patients (median age
50 years) completed the planned questionnaires until 6 weeks post radiation. Twenty (87%) patients had primary brain tumors
whereas three (13%) patients had metastatic lesions in brain. Of the 23 patients, 14 patients (60.86%) had abnormal or increased
daytime sleepiness; of which 3 had ESS scores greater than 16. Conclusion: Somnolence was noted in 60.86% of the patients,
which is in accordance with existing literature. Epworth sleepiness scale is an effective tool to detect and quantify somnolence,
However, it does not consider other symptoms of somnolence syndrome and hence should be combined with visual analog scale
to get complete information.
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Introduction
Malignant tumors of the brain are either primary or meta-
static, the latter being more common. Metastases commonly
arise from lung, breast, colo-rectum, etc.1 The primary tu-
mors are most often neuro-epithelial in origin; namely as-
trocytomas, oligodendrogliomas, ependymomas, amongst
others. As for any malignancy, the three broad treatment
options are surgery, radiation therapy and chemotherapy.
Radiation therapy forms the mainstay of treatment, either
alone or in an adjuvant setting. In view of the blood brain
barrier, chemotherapy has limited role, commonly as a ra-
dio-sensitizer in high grade gliomas. Radiotherapy plays the
prime role in management of brain metastases. The most
time tested modality is whole brain radiotherapy, commonly
to a dose of 20- 30 Gy in 5 to 10 fractions. Radiotherapy also
plays a key role in primary brain tumors. The treatment in-
volves maximal safe resection followed by adjuvant radiation
to a dose of 54 to 60 Gy with or without chemotherapy de-
pending upon histology and grade of the tumor.
Radiotherapy causes a number of adverse effects- and have
been divided into acute, sub-acute and delayed. Acute effects
occur during radiation and up to 6 weeks of completing ra-
diation. They can present with transient worsening of
pre-treatment deficits during radiotherapy or can manifest as
general symptoms like fatigue, headache, and drowsiness.
Late effects include neuro-cognitive dysfunction and brain
necrosis.
Sub-acute or early delayed effects include head ache, fatiga-
bility and somnolence syndrome. Although early and de-
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layed effects are well documented, Somnolence syndrome is
less studied. Commonly, general symptom assessment and
ranking on visual analog scale are undertaken to study this
syndrome.2, 3
Epworth Sleepiness Scale (ESS) is an instrument to measure
day time sleepiness and is a useful tool to diagnose sleep dis-
turbances.4 On the basis of scores obtained, propensity to
sleep can be categorized and this can potentially help to
quantify somnolence. This study is undertaken to study the
incidence of somnolence in the patients in our department
receiving radiotherapy to brain using Epworth Sleepiness
Scale.
Methods and Materials
Patient population
This is a prospective study based on the patients with histo-
logically proven primary brain tumors or brain metastases
treated in our department with radiation therapy from Janu-
ary 2013 to December 2013. Patient demographics and tu-
mor type- primary or metastatic along with grade was noted.
Patients with Karnofsky performance status less than 70 and
those with pre-existing sleep disorders were excluded from
the study.
Treatment
Patients with primary brain tumors were subjected to initial
surgery ranging from stereotactic biopsy to total decompres-
sion followed by radiation therapy to a dose of 5400 to 5940
cGy in conventional fractionation depending upon the his-
tology and grade of the lesion. The post-op tumor bed along
with residual disease with adequate margins were the vol-
umes of interest. Metastatic brain tumors were treated with
whole brain radiotherapy to a dose of 3000cGy in 10 frac-
tions as per departmental protocol.
FIG. 1: Epworth Sleepiness Scale.4
Assessment for somnolence
Patients were subjected to Epworth Sleepiness Scale4 (Figure
1) at baseline, thereafter every week during radiation; also
continuing weekly after cessation of radiation until 6 weeks
post treatment.
Results
Demography, Tumor characteristics and Performance
status
Twenty three patients were assessed and all completed the
questionnaire weekly during treatment and for 6 weeks post
treatment. Patients’ age ranged from 25 to 65 years with a
mean of 47.7 years and median of 50 years. 13 patients were
males and 10 were females.
Twenty patients had primary brain tumors and 3 patients
had metastatic disease (Figure 2). Two patients had metasta-
ses from primaries in the breast while one had from testes.
Of the 20 patients with primary brain malignancies, 1 pa-
tient had primary central nervous system melanoma, one
had papillary tumor of pineal region and 18 had gliomas, of
which one was low grade and 17 were high grade gliomas.
The Karnofsky Performance Scale (KPS) ranged from 70 to
90. Twelve patients had a KPS of 90 while 5 had a KPS of 80
and 6 had a KPS of 70.
FIG. 2: Pie chart showing tumor characteristics of the patients.
Assessment of somnolence
Of the 23 patients (Figure 3), 14 patients (60.86%) had in-
creased daytime sleepiness. Three out of these 14 (21.4%)
patients were severely sleepy (ESS score: 16-24).
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FIG. 3: Pie chart showing patients sleepiness ESS scores.
One out of the 3 patients (33%) with brain metastases de-
veloped somnolence. In the remaining 13 sleepy patients
who had primary brain tumors, increase in ESS scores oc-
curred at 5- 6 weeks post radiotherapy in 9 patients and ear-
lier in the remaining 4 patients (3 patients in 2nd week and 1
patient in 4th week).
Discussion
Somnolence syndrome is an early-delayed side effect of radi-
ation treatment to the brain. The condition was first docu-
mented by Druckmann in 1929, when treating children for
ringworm of the scalp with 150kV X-ray.5 It has generally
become recognised as a condition affecting children with
acute lymphocytic leukemia (ALL) after receiving prophy-
lactic cranial irradiation.6, 7However, studies have begun to
report that somnolence also appears in adults after irradia-
tion for primary brain tumours.2, 3
In the present study, we have found an incidence of exces-
sive sleepiness (one of the symptoms of somnolence syn-
drome) in 60.86 % of the individuals, which is in concord-
ance the 62.9% incidence reported by Parker et al.8 in chil-
dren receiving cranial irradiation. In the latter study, EEG
changes like pathological symmetric slowing of the domi-
nant rhythm and excessive diffuse theta components were
used as a method to detect presence of somnolence.
Faithfull S and Brada M reported incidence of somnolence
syndrome in 16 of 19 patients (84.2%).2 This is considerably
higher than our reported findings. They have used a pro-
spective diary using visual analog scales of common somno-
lence symptoms and fatigue. They found that although pa-
tients experienced increased drowsiness, lethargy, clumsiness
and slow mental processes, they did not require more sleep.
Patients commented on the symptoms being ‘a sensation that
was mentally disabling and a disruption to physical activity
by an overwhelming feeling of exhaustion’. Assessment of
other symptoms along with propensity to sleep could have
resulted in the higher somnolence rates in their study.
The timing of somnolence correlates well with other re-
ported literature; i.e., the symptoms most commonly begin at
5-6 weeks post radiation therapy.9 However Faithfull and
Brada reported a distinct pattern.2 They found that all pa-
tients in their study developed symptoms two weeks
post-treatment completion. Symptoms then resolved only to
resurface in the fifth week, lasting two to five days. Like all
other studies, such a bimodal presence of somnolence was
not found in our study.
Epworth Sleepiness Scale is a validated eight-item question-
naire wherein the subject is asked to rate on a four point
scale (0-3) his/her likelihood of falling asleep in 8 different
situations. Scores range from 0 (the least sleepy) to 24 (the
most sleepy). The higher the score, the higher the level of
persons’ daytime sleepiness. Scores equal to or above 10 are
interpreted as increased daytime sleepiness.
The Epworth Sleepiness Scale has been validated in sleep
disorders using Multiple Sleep Latency Test.3 Multiple sleep
latency tests measure the propensity to fall asleep when the
patient is given 4-5 programmed 20 to 40 minute nap op-
portunities 2 hours apart during daytime with EEG, EOG
and EMG monitoring. In our study, sleep latency monitoring
has not been done.
The use of Epworth Sleepiness Scale in assessing somnolence
syndrome in patients receiving radiation therapy to brain is a
novel approach and has been used in in only one previously
reported study in the surveyed literature till date. Azita Gi-
lardi from University of California- Los Angeles has used
Epworth Sleepiness Scale along with other scales and an
actigraphic watch to measure somnolence.10 It is an easily
available and a simple questionnaire. Besides, it can effec-
tively grade the severity of somnolence based on the scores
being 11-15 and 16-24.
The major limitation of using the ESS alone in assessing ra-
diation induced somnolence, is that it can detect only in-
creased sleepiness from the spectrum of symptoms encom-
passing this entity, which can range from mild drowsiness to
extreme exhaustion, low-grade fever, nausea, anorexia and
headache. Besides, the self-scoring and gradation of scoring
in the ESS introduce an element of subjectivity. Hence, using
the Epworth Sleepiness Scale along with assessment of
common symptoms of somnolence syndrome and addition of
an objective tool like Littman scale6 will be more accurate in
making a definitive diagnosis of somnolence syndrome.
Merits of the study
It is a prospective study. To the best of our knowledge, it is
the first study using Epworth Sleepiness Scale as the sole tool
to assess post radiation somnolence syndrome
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Limitations
The sample size is small and only 3 patients had metastatic
brain cancer. Hence, a meaningful comparison of somno-
lence at various doses could not be undertaken.
Future prospective
Epworth Sleepiness Scale can be used along with visual ana-
log scale for assessment. Together, the symptomatology will
be better understood along with quantification of somno-
lence.
Conclusion
Somnolence occurred in 60.86% of the patients who under-
went radiation treatment for brain tumors, which is in ac-
cordance with existing literature. Epworth Sleepiness Scale is
an effective tool to assess somnolence. However, it assesses
for only one of the components of somnolence syndrome. It
will be ideal to combine it with scales for assessment of other
relevant symptoms.
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